Literature DB >> 22723097

Hybridoma technology for the generation of monoclonal antibodies.

Chonghui Zhang1.   

Abstract

Hybridoma technology has long been a remarkable and indispensable platform for generating high-quality monoclonal antibodies (mAbs). Hybridoma-derived mAbs have not only served as powerful tool reagents but also have emerged as the most rapidly expanding class of therapeutic biologics. With the establishment of mAb humanization and with the development of transgenic-humanized mice, hybridoma technology has opened new avenues for effectively generating humanized or fully human mAbs as therapeutics. In this chapter, an overview of hybridoma technology and the laboratory procedures used routinely for hybridoma generation are discussed and detailed in the following sections: cell fusion for hybridoma generation, antibody screening and characterization, hybridoma subcloning and mAb isotyping, as well as production of mAbs from hybridoma cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22723097     DOI: 10.1007/978-1-61779-931-0_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  20 in total

1.  Biomimetic Targeting of Nanoparticles to Immune Cell Subsets via Cognate Antigen Interactions.

Authors:  Brian T Luk; Yao Jiang; Jonathan A Copp; Che-Ming J Hu; Nishta Krishnan; Weiwei Gao; Shulin Li; Ronnie H Fang; Liangfang Zhang
Journal:  Mol Pharm       Date:  2018-03-16       Impact factor: 4.939

2.  Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.

Authors:  Flavia Chiuppesi; Felix Wussow; Erica Johnson; Chao Bian; Meng Zhuo; Augustine Rajakumar; Peter A Barry; William J Britt; Rana Chakraborty; Don J Diamond
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

3.  Characterization of monoclonal antibodies that specifically differentiate field isolates from vaccine strains of classical swine fever virus.

Authors:  Shijiang Mi; Lihua Wang; Hongwei Li; Fei Bao; Rachel Madera; Xiju Shi; Liying Zhang; Yingying Mao; Renhe Yan; Xianzhu Xia; Wenjie Gong; Jishu Shi; Changchun Tu
Journal:  Front Immunol       Date:  2022-07-19       Impact factor: 8.786

4.  Development of a Colloidal Gold-based Immunochromatographic Test Strip for Detection of Cetacean Myoglobin.

Authors:  Kun-Wei Chan; Chieh Lo; Chi-Shih Chu; Li-Te Chin; Yu-Ting Wang; Wei-Cheng Yang
Journal:  J Vis Exp       Date:  2016-07-13       Impact factor: 1.355

5.  Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases.

Authors:  Aishwarya Mary Johnson; Robert Barigye; Hariharan Saminathan
Journal:  Hum Vaccin Immunother       Date:  2021-05-11       Impact factor: 3.452

6.  Preclinical Analysis of Candidate Anti-Human CD79 Therapeutic Antibodies Using a Humanized CD79 Mouse Model.

Authors:  Scott M Wemlinger; Chelsea R Parker Harp; Bo Yu; Ian R Hardy; Matthew Seefeldt; Jennifer Matsuda; Michael Mingueneau; Kerri A Spilker; Thomas O Cameron; James W Larrick; Andrew Getahun; John C Cambier
Journal:  J Immunol       Date:  2022-03-23       Impact factor: 5.426

Review 7.  Challenges in Antibody Development against Tn and Sialyl-Tn Antigens.

Authors:  Liliana R Loureiro; Mylène A Carrascal; Ana Barbas; José S Ramalho; Carlos Novo; Philippe Delannoy; Paula A Videira
Journal:  Biomolecules       Date:  2015-08-11

Review 8.  Antibody Engineering for Pursuing a Healthier Future.

Authors:  Abdullah F U H Saeed; Rongzhi Wang; Sumei Ling; Shihua Wang
Journal:  Front Microbiol       Date:  2017-03-28       Impact factor: 5.640

Review 9.  Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives.

Authors:  Hilal Ahmed Parray; Shivangi Shukla; Sweety Samal; Tripti Shrivastava; Shubbir Ahmed; Chandresh Sharma; Rajesh Kumar
Journal:  Int Immunopharmacol       Date:  2020-05-27       Impact factor: 4.932

10.  Development of an anti-human complement C6 monoclonal antibody that inhibits the assembly of membrane attack complexes.

Authors:  Kimberly Lin; Lingjun Zhang; Michael Kong; Maojing Yang; Yinghua Chen; Earl Poptic; Melanie Hoffner; Jijun Xu; Connie Tam; Feng Lin
Journal:  Blood Adv       Date:  2020-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.